Figure 2.
Overall survival estimates in 319 patients with WM treated with ibrutinib monotherapy, for the entire cohort (A), according to age (B), and according to the IPSSWM in patients who received ibrutinib as primary therapy (C).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.